
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc has demonstrated solid revenue growth in its key segments, with Cell Processing revenue reaching $23.0 million, reflecting a 28% increase year-over-year, and evo and Thaw revenue increasing to $2.5 million, up 44% year-over-year. The company is also raising its 2025 revenue guidance to a range of $100-103 million, indicating a projected 22-25% year-over-year growth, bolstered by strong expectations for Cell Processing and evo/Thaw products. Furthermore, management anticipates a reduction in net loss and an expansion of adjusted EBITDA margin, reinforcing a strong growth momentum moving forward.
Bears say
BioLife Solutions Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to lower-than-expected growth projections for its products and services. The company's substantial net loss of $15.8 million, resulting from high research and development expenses associated with the PanTHERA transaction, further underscores financial instability. Additionally, management has revised FY2025 revenue guidance downward by approximately $8 million, indicating potential hurdles in achieving the anticipated 27-29% year-over-year growth in the Cell Processing platform revenue.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares